TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06389877: A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)

Sponsor: Beam Therapeutics Inc. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 192 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$338,640

Rescue Site Savings

+$225,760

Unlock Full NCT06389877 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06389877 Rescue Dossier →